Article Versions Notes

Siebert N, Troschke-Meurer S, Marx M, Zumpe M, Ehlert K, Gray J, Garaventa A, Manzitti C, Ash S, Klingebiel T, et al. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers. 2018; 10(10):387. https://doi.org/10.3390/cancers10100387

Siebert, Nikolai, Sascha Troschke-Meurer, Madlen Marx, Maxi Zumpe, Karoline Ehlert, Juliet Gray, Alberto Garaventa, Carla Manzitti, Shifra Ash, Thomas Klingebiel, and et al. 2018. "Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial" Cancers 10, no. 10: 387. https://doi.org/10.3390/cancers10100387

Siebert, N., Troschke-Meurer, S., Marx, M., Zumpe, M., Ehlert, K., Gray, J., Garaventa, A., Manzitti, C., Ash, S., Klingebiel, T., Beck, J., Castel, V., Valteau-Couanet, D., Loibner, H., Ladenstein, R., & Lode, H. N. (2018). Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial. Cancers, 10(10), 387. https://doi.org/10.3390/cancers10100387